QbD-driven optimization of cilnidipine-loaded spanlastic vesicles using central composite design for enhanced transdermal permeation across rat abdominal skin

Read full text Summarise with VIRAT
Authors: Yonghui Zheng, Lihua Qian, Shengkai Tong
Cited by: 0
References: 10

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

How can a poorly water-soluble antihypertensive agent like cilnidipine be reformulated to bypass hepatic first-pass metabolism while maintaining therapeutic plasma concentrations over a 24-hour dosing interval? This research applied a Quality by Design (QbD) framework to systematically develop and optimize cilnidipine-loaded spanlastic vesicles intended for transdermal delivery across rat abdominal skin. The Quality Target Product Profile (QTPP) was defined as elastic nanovesicles with a mean particle diameter below 200 nm, entrapment efficiency exceeding 75%, polydispersity index under 0.3, and a steady-state transdermal flux greater than 15 µg/cm²/h. Critical Material Attributes and Critical Process Parameters were identified through an Ishikawa cause-and-effect analysis. A Plackett-Burman screening design first isolated Span 60 concentration, Tween 80 concentration, and probe sonication time as the three most influential variables. These factors were then arranged in a 3-factor, 5-level central composite design (CCD) comprising 20 experimental runs, including six axial points and six centre-point replicates. Vesicle size, entrapment efficiency, and transdermal flux served as Critical Quality Attributes (CQAs). Quadratic polynomial regression models fitted through Design-Expert® software explained more than 96% of the observed variability (adjusted R² > 0.94 for each response). The overlay plot and desirability function converged on an optimized formulation containing 3.2% w/v Span 60, 1.4% w/v Tween 80, and 8.5 minutes of sonication time. Checkpoint verification batches confirmed vesicle size of 172.4±3.8 nm, entrapment efficiency of 82.7±1.9%, PDI of 0.21±0.02, and transdermal flux of 18.6±0.7 µg/cm²/h across excised rat abdominal skin, all within 95% prediction intervals. Differential scanning calorimetry and Fourier-transform infrared spectroscopy indicated molecular dispersion of the drug within the bilayer without chemical interaction. Confocal laser scanning microscopy revealed penetration of rhodamine-labelled vesicles up to 147 µm into dermal tissue, compared with 43 µm for a plain drug solution. The QbD-guided CCD approach provided a robust design space for cilnidipine spanlastics, offering a viable transdermal alternative to oral dosing.

Fields of Study & Subjects

Advancements in Transdermal Drug Delivery Advanced Drug Delivery Systems Drug Solubulity and Delivery Systems

Publication details

Journal / source
International Journal of Pharmaceutical Sciences and Drug Analysis
Volume
6
Issue
1
Pages
14–20
Publication date
1 January 2026
Language
EN